GITR ligand fusion protein agonist enhances the tumor antigen–specific CD8 T-cell response and leads to long-lasting memory

Rationale for anti-GITR cancer immunotherapy

(2016) Deborah A. Knee et al.   EUROPEAN JOURNAL OF CANCER

Enhanced CD8 T Cell Responses through GITR-Mediated Costimulation Resolve Chronic Viral Infection

(2015) Maria Fernanda Pascutti et al.   PLoS Pathogens

GITR agonist enhances vaccination responses in lung cancer

(2015) Li X Zhu et al.   OncoImmunology

Immunogenicity of Murine Solid Tumor Models as a Defining Feature of In Vivo Behavior and Response to Immunotherapy

(2013) Melissa G. Lechner et al.   JOURNAL OF IMMUNOTHERAPY

Stimulation of the Glucocorticoid-Induced TNF Receptor Family-Related Receptor on CD8 T Cells Induces Protective and High-Avidity T Cell Responses to Tumor-Specific Antigens

(2010) A. L. Cote et al.   JOURNAL OF IMMUNOLOGY

GITR Triggering Induces Expansion of Both Effector and Regulatory CD4+ T Cells In Vivo

(2009) R. W. van Olffen et al.   JOURNAL OF IMMUNOLOGY